Dapirolizumab Pegol Improves Disease Activity in Systemic Lupus Erythematosus: Evidence from Phase 3 PHOENYCS GO Trial and Prior Studies

MedXY Editorial Team•Sep 22, 2026•Clinical Updates

Dapirolizumab pegol, a PEGylated anti-CD40 ligand Fab’ fragment, shows significant efficacy in improving moderate-to-severe systemic lupus erythematosus (SLE) disease activity at 48 weeks.
The large, multinational, randomized, double-blind, placebo-controlled PHOENYCS GO phase 3 trial demonstrated superior British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response rates with dapirolizumab compared to placebo.
Pharmacokinetic and exposure-response modeling support sustained drug exposure as important for maintaining clinical response.
Prior phase 1/2 studies indicate a favorable safety profile without increased thromboembolic risks, a known concern with CD40 ligand targeting therapies.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Dapirolizumab pegol, a PEGylated anti-CD40 ligand Fab’ fragment, shows significant efficacy in improving moderate-to-severe systemic lupus erythematosus (SLE) disease activity at 48 weeks.
The large, multinational, randomized, double-blind, placebo-controlled PHOENYCS GO phase 3 trial demonstrated superior British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response rates with dapirolizumab compared to placebo.
Pharmacokinetic and exposure-response modeling support sustained drug exposure as important for maintaining clinical response.
Prior phase 1/2 studies indicate a favorable safety profile without increased thromboembolic risks, a known concern with CD40 ligand targeting therapies.